Search
Acetophenazine
go.drugbank.com/drugs/DB01063ApprovedIt primarily targets the dopamine D2 receptor.
Categories: Dopamine D2 Receptor AntagonistsIrbesartan
go.drugbank.com/drugs/DB01029ApprovedInvestigational[L7459] Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.[L7456,L7459] Irbesartan was granted FDA approval on 30 September 1997.[L7456,L7459] … [L7456,L7459] It can also be used as part of a combination product with [hydrochlorothiazide] for patients not well controlled or not expected to be well controlled on monotherapy.
Mixtures: DIOGENA-DRA, IRBESARTAN/HCT 1A 150/12.5Products: IRBESARTAN 1A PHARMA 75MG, IRBESARTAN 1A PHARMA 150MGPeginterferon alfa-2b
go.drugbank.com/drugs/DB00022ApprovedInvestigationalApproved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with [Ribavirin] or other antiviral drugs [FDA Label]. … Peginterferon alfa-2b is available as a variable dose injectable product (tradename Pegintron) used for the treatment of chronic Hepatitis C.
Categories: Compounds used in a research, industrial, or household settingVosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigational[L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention … of a peptidase-resistant formulation has allowed for its use as a viable treatment option in achondroplasia.
Tildrakizumab
go.drugbank.com/drugs/DB14004ApprovedInvestigationalThe approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter [L1858]. … Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis [A32255].
Trametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigational[L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a … [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexTerazosin
go.drugbank.com/drugs/DB01162ApprovedInvestigationalTerazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831].
Products: TERAZOSIN 1A PHARMA 2MG, TERAZOSIN 1A PHARMA 5MGElapegademase
go.drugbank.com/drugs/DB14712ApprovedElapegademase is a PEGylated recombinant adenosine deaminase. … It can be defined molecularly as a genetically modified bovine adenosine deaminase with a modification in cysteine 74 for serine and with about 13 methoxy polyethylene glycol chains bound via carbonyl
Synonyms: (74-SERINE (C>S),245-THREONINE (A>T))BOS TAURUS ADENOSINE DEAMINASE (BOVINE ADENOSINE AMINOHYDROLASE, EC=3.5.4.4)-(1-356)-PEPTIDE PRODUCED IN ESCHERICHIA COLI, AN AVERAGE OF 13 RESIDUES ARE SUBSTITUTEDSparteine
go.drugbank.com/drugs/DB06727ApprovedWithdrawnIt is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. … Sparteine is a plant alkaloid derived from _Cytisus scoparius_ and _Lupinus mutabilis_ which may chelate calcium and magnesium.
Categories: Antiarrhythmics, Class IaMisoprostol
go.drugbank.com/drugs/DB00929ApprovedInvestigational[A181586] Misoprostol was granted FDA approval on 27 December 1988.[L7616] … Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions.
Mixtures: DICLOENAC SODIUM and MISOPROSTOL DR, Diclofenac sodium and Misoprostol DR